Page last updated: 2024-11-02

oxymetazoline and Rhinitis, Allergic, Nonseasonal

oxymetazoline has been researched along with Rhinitis, Allergic, Nonseasonal in 13 studies

Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.

Research Excerpts

ExcerptRelevanceReference
"105 patients collected from chronic simple rhinitis, chronic hypertrophic rhinitis and perennial allergic rhinitis were treated with daphnlin spray (daphnlin group) or ephedrine spray (ephedrine group)."3.70[The curative effect of daphnlin spray on treating rhinitis]. ( Huang, X; Tan, H; Yue, J, 1999)
"The purpose of this review is to present data on nasal reactivity to methacholine, histamine and allergen in normal subjects, patients with common colds, perennial rhinitis and hay-fever."3.66Nasal reactivity in rhinitis. ( Borum, P; Brofeldt, S; Grønborg, H; Mygind, N, 1983)
"Oral prednisone pretreatment significantly reduced the mean of each subject's peak late-phase concentration of both MBP (30."2.66Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. ( Bascom, R; Dunnette, S; Gleich, GJ; Lichtenstein, LM; Naclerio, RM; Pipkorn, U; Proud, D, 1989)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19902 (15.38)18.7374
1990's4 (30.77)18.2507
2000's2 (15.38)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, W1
Zhou, L1
Zeng, Q1
Luo, R1
Luong, A1
Cheung, EJ1
Citardi, MJ1
Batra, PS1
Baroody, FM1
Brown, D1
Gavanescu, L1
DeTineo, M1
Naclerio, RM2
Keiser, PB1
Nelson, MR1
Wandalsen, GF1
Mendes, AI1
Solé, D1
Yue, J1
Huang, X1
Tan, H1
Borum, P1
Grønborg, H1
Brofeldt, S1
Mygind, N1
Ticoll, B1
Shugar, G1
Ferguson, BJ1
Paramaesvaran, S1
Rubinstein, E1
Willsie, SK1
Selner, JC1
Koepke, JW1
Staudenmayer, H1
Dolen, WK1
Glover, GC1
Linzmayer, MI1
Mooney, JJ1
Wiener, MB1
Lau, SK1
Wei, WI1
Van Hasselt, CA1
Sham, CL1
Woo, J1
Choa, D1
Engzell, UC1
Bascom, R1
Pipkorn, U1
Proud, D1
Dunnette, S1
Gleich, GJ1
Lichtenstein, LM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa[NCT00584987]Phase 464 participants (Actual)Interventional2007-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

RQLQ Score [2 Weeks]

The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed 2 weeks after initiation of treatment regimen

Interventionunits on a scale (Mean)
Placebo FF + Placebo OXY2.20
FF + Placebo OXY2.03
Placebo FF + OXY2.11
FF + OXY1.62

RQLQ Score [4 Weeks]

The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed 4 weeks after initiation of treatment regimen

Interventionunits on a scale (Mean)
Placebo FF + Placebo OXY1.75
FF + Placebo OXY1.37
Placebo FF + OXY1.85
FF + OXY1.26

RQLQ Score [6 Weeks]

The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed 6 weeks after initiation of treatment regimen

Interventionunits on a scale (Mean)
Placebo FF + Placebo OXY1.85
FF + Placebo OXY1.83
Placebo FF + OXY2.03
FF + OXY1.55

RQLQ Score [Baseline]

The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed at baseline

Interventionunits on a scale (Mean)
Placebo FF + Placebo OXY3.07
FF + Placebo OXY3.25
Placebo FF + OXY2.99
FF + OXY2.60

Total Nasal Congestion Symptom Score

The severity of nasal congestion was recorded in the morning (reflective of symptoms overnight) and evening (reflective of daytime symptoms) on a 0 to 3 scale. The total nasal congestion symptom score was obtained by adding the symptoms obtained on all 28 days of treatment. Values for this outcome are in the range of 0 to 168 (i.e., 6 x 28). Congestion scores increase with congestion severity (i.e., higher numbers correspond to worse congestion). (NCT00584987)
Timeframe: 28 days of treatment

Interventionunits on a scale (Median)
Placebo FF + Placebo OXY94
FF + Placebo OXY70
Placebo FF + OXY75
FF + OXY68

Total NPIF

Nasal peak inspiratory flow (NPIF) is a physiological measure of nasal airflow which is particularly sensitive to nasal valve collapse. NPIF was measured objectively in liters per minute with an In-Check Peak Inspiratory FlowMeter (Ferraris Medical Inc, Orchard Park, NY). Subjects obtained 3 readings every morning and every evening and recorded the best flow measured. The morning and evening NPIF measurements were summed for days 2 through 28 of the treatment cycle, yielding the total NPIF outcome measure. NPIF scores increase with air flow quality (i.e., higher NPIF values are indicative of better nasal air flow). (NCT00584987)
Timeframe: days 2 through 28 of the treatment cycle

Interventionliters per minute (Median)
Placebo FF + Placebo OXY5240
FF + Placebo OXY5680
Placebo FF + OXY4485.5
FF + OXY5520

Reviews

1 review available for oxymetazoline and Rhinitis, Allergic, Nonseasonal

ArticleYear
Improved strategies and new treatment options for allergic rhinitis.
    The Journal of the American Osteopathic Association, 2002, Volume: 102, Issue:6 Suppl 2

    Topics: Administration, Intranasal; Beclomethasone; Cromolyn Sodium; Histamine H1 Antagonists; Humans; Immun

2002

Trials

6 trials available for oxymetazoline and Rhinitis, Allergic, Nonseasonal

ArticleYear
Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial.
    Scientific reports, 2017, 01-18, Volume: 7

    Topics: Adenoids; Case-Control Studies; Child; Demography; Female; Humans; Hypertrophy; Male; Mometasone Fur

2017
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis.
    The Journal of allergy and clinical immunology, 2011, Volume: 127, Issue:4

    Topics: Administration, Intranasal; Adult; Androstadienes; Anti-Inflammatory Agents; Double-Blind Method; Dr

2011
A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2001, Volume: 125, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Budesonide; Double-Blind Method; Female; Humans; Male; Middle Aged;

2001
Assessment of nasal patency by rhinoscopic measurement of cross sectional nasal airway area: correlation with subjective nasal symptoms.
    Annals of allergy, 1991, Volume: 66, Issue:1

    Topics: Adult; Endoscopy; Ephedrine; Female; Humans; Male; Nasal Cavity; Nasal Decongestants; Oxymetazoline;

1991
A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis.
    Asian Pacific journal of allergy and immunology, 1990, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aerosols; Aged; Benzhydryl Compounds; Bronchodilator Agents; Budesonide; Double-B

1990
Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx.
    The Journal of allergy and clinical immunology, 1989, Volume: 84, Issue:3

    Topics: Blood Proteins; Cell Movement; Double-Blind Method; Eosinophil Granule Proteins; Eosinophil-Derived

1989

Other Studies

6 other studies available for oxymetazoline and Rhinitis, Allergic, Nonseasonal

ArticleYear
Evaluation of optical rhinometry for nasal provocation testing in allergic and nonallergic subjects.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2010, Volume: 143, Issue:2

    Topics: Administration, Intranasal; Adult; Allergens; Female; Histamine; Humans; Oxymetazoline; Rhinitis, Al

2010
Baseline differences explain the apparent benefits of combining oxymetazoline with intranasal corticosteroids.
    The Journal of allergy and clinical immunology, 2011, Volume: 128, Issue:5

    Topics: Androstadienes; Anti-Inflammatory Agents; Female; Humans; Male; Nasal Decongestants; Oxymetazoline;

2011
Correlation between nasal resistance and different acoustic rhinometry parameters in children and adolescents with and without allergic rhinitis.
    Brazilian journal of otorhinolaryngology, 2012, Volume: 78, Issue:6

    Topics: Adolescent; Airway Resistance; Case-Control Studies; Child; Humans; Nasal Cavity; Nasal Decongestant

2012
[The curative effect of daphnlin spray on treating rhinitis].
    Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology, 1999, Volume: 13, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Ephedrine; Female; Humans; Male; Middle Aged; Nasal D

1999
Nasal reactivity in rhinitis.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 1)

    Topics: Allergens; Animals; Common Cold; Female; Histamine; Humans; Male; Methacholine Chloride; Methacholin

1983
Paranoid psychosis induced by oxymetazoline nasal spray.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1994, Feb-01, Volume: 150, Issue:3

    Topics: Administration, Intranasal; Adult; Humans; Male; Oxymetazoline; Paranoid Disorders; Rhinitis, Allerg

1994